icer glp-1 Affordable Access to Obesity Medications: Strategies to Guide Market Action & Policy Solutions ICER Releases Cost Analysis Report
Description
Change in HbA1c, eGFR, and cholesterol levels Biomarker values were assessed in posttreatment selected patients who were alive and had a measurement of the respective biomarker before and 312 months after treatment initiation, as the first available measurement within 12 months after treatment initiation
Media contact Amy Thibault 401-318-2865 [email protected] View original content to download multimedia: SOURCE CVS Health
Pandey A, Patel KV, Segar MW, Ayers C, Linge J, Leinhard OD, et al
It presents their discovery of a GLP-1 oral solution as a turning point in their NHS routine, implying that NHS staff themselves are using the product
10.1152/ajpregu.1996.271.4.R848 [DOI] [PubMed] [Google Scholar] Thorens, B
